Similar to the mutant p53 NSCLC and PDAC cells used in this study, we expect that higher concentrations of olaparib are required to induce synergistic treatment responses in combination with AF in both 2D and 3D 344SQ cultures. This evidence concerns the gene TP53 and non-small cell lung carcinoma.